GlobeNewswire

Eight International Companies Presented at the First Nasdaq International Designation Virtual Investor Conference

Dela

NEW YORK, June 06, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) completed its first Nasdaq International Designation Virtual Investor Conference on June 1, 2017. Participating companies of the Nasdaq International Designation program joined the online conference to present their current state of business to a broad audience and potential investors. The conference also provided individual and institutional investors an opportunity to engage with CEOs, CFOs, and IROs from a wide range of sectors globally.

Full conference and presentation materials are available at the following links:

Full Conference 
http://edge.media-server.com/m/p/tnqwsb3a

Qantas Airways Ltd - Australia 
ASX: QAN, OTC - Nasdaq International Select: QABSY
Alan Joyce - Chief Executive Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/57

Continental AG - Germany
ETR: CON, OTC - Nasdaq International Select: CTTAY
Klaus Paesler - Manager, Investor Relations
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/1437

Cielo S.A.  - Brazil
SAO: CIEL3, OTC: CIOXY
Andre Cazotto - Investor Relations Manager
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/2915

Cyberdyne Inc - Japan
TYO: 7779, OTC - Nasdaq International Select: CYBQY
Shinji Uga - Chief Financial Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/4532.5

BE Semiconductor Industries N.V. - Netherlands
Euronext Amsterdam: BESI, OTC - Nasdaq International: BESIY
Richard Blickman - Chief Executive Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/5568

Roxgold Inc. - Canada
TSX:ROXG, OTC - Nasdaq International: ROGFF
John Dorward - President, Chief Executive Officer and Director
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/6963

Audio Pixels Holdings - Australia
ASX: AKP, OTC - Nasdaq International: ADPXY
Danny Lewin - Founder, Chief Executive Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/8177.5

Freshii Inc - Canada
TSE: FRII, OTC: FRHHF
Matt Corrin - Chief Executive Officer
http://edge.media-server.com/m/p/tnqwsb3a/clip_start_position/9370.5

About The Nasdaq International Designation 
Launched in December 2015, the Nasdaq International Designation program is designed for non-U.S.-based companies that have level 1 American Depository Receipts or shares that trade in the over-the-counter (OTC) market. The program offers a unique partnership with Nasdaq that provides member companies with Nasdaq's robust visibility offering which allows for greater access to US investors, and can potentially increase liquidity. The Nasdaq International Designation is home to a diverse range of companies in innovative industries across the globe. Total Market Cap of Member Companies exceeds $140B and program members hail from Australia, Japan, Germany, Brazil, Canada, the U.K., and the Netherlands.

As a comprehensive program, companies receive a full service offering that includes investor relations tools and services, as well as access to Nasdaq's visibility assets to enhance communication with the investment community. In the past year, members of the program were invited to the Nasdaq MarketSite with the opportunity to amplify their brand activities through different channels.

If you are interested in the Nasdaq International Designation Program, learn more at http://business.nasdaq.com/list/international-designation

About Nasdaq:
Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11.0 trillion. To learn more, visit: http://business.nasdaq.com

-NDAQG-

Nasdaq Media Relations Contact:
Stephanie Lowenthal
+1 (646) 441-5073
Stephanie.Lowenthal@nasdaq.com

Emily Pan
+1(646) 441-5120
emily.pan@nasdaq.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nasdaq via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum